AMARIN CORP PLC\UK Deferred Income Tax Expense (Benefit)
AMARIN CORP PLC\UK (AMRN) reported Deferred Income Tax Expense (Benefit) of $11.08 million for the 12-month period ending 2017-12-31, per its 10-K filed 2020-02-25.
Discontinued › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2020-02-25
- AMARIN CORP PLC\UK deferred income tax expense (benefit) for the quarter ending 2016-12-31 was $11.93M.
- AMARIN CORP PLC\UK deferred income tax expense (benefit) for the quarter ending 2016-09-30 was -$1.29M.
- AMARIN CORP PLC\UK deferred income tax expense (benefit) for the quarter ending 2016-06-30 was -$1.40M.
- AMARIN CORP PLC\UK deferred income tax expense (benefit) for the quarter ending 2016-03-31 was -$446.00K.
- AMARIN CORP PLC\UK deferred income tax expense (benefit) for fiscal 2017 was $11.08M, a 25.96% increase from fiscal 2016.
- AMARIN CORP PLC\UK deferred income tax expense (benefit) for fiscal 2016 was $8.80M.
- AMARIN CORP PLC\UK deferred income tax expense (benefit) for fiscal 2015 was -$4.25M.
- AMARIN CORP PLC\UK deferred income tax expense (benefit) for fiscal 2014 was -$3.61M.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 6 month | Deferred Income Tax Expense (Benefit) 9 month | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2017-12-31 | $11.08M 10-K · filed 2020-02-25 | |||
| 2016-12-31 | $11.93M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $10.64M derived: sum of 2 quarters · filed 2019-02-27 | $9.24M derived: sum of 3 quarters · filed 2019-02-27 | $8.80M 10-K · filed 2019-02-27 |
| 2016-09-30 | -$1.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | -$2.69M derived: sum of 2 quarters · filed 2017-11-01 | -$3.13M 10-Q · filed 2017-11-01 | -$5.80M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-06-30 | -$1.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | -$1.85M 10-Q · filed 2017-08-02 | -$4.52M derived: sum of 3 quarters · filed 2018-02-27 | -$5.37M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-03-31 | -$446.00K 10-Q · filed 2017-05-03 | -$3.12M derived: sum of 2 quarters · filed 2018-02-27 | -$3.97M derived: sum of 3 quarters · filed 2018-02-27 | -$4.60M derived: sum of 4 quarters · filed 2018-02-27 |
| 2015-12-31 | -$2.67M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | -$3.52M derived: sum of 2 quarters · filed 2018-02-27 | -$4.16M derived: sum of 3 quarters · filed 2018-02-27 | -$4.25M 10-K · filed 2018-02-27 |
| 2015-09-30 | -$851.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | -$1.49M derived: sum of 2 quarters · filed 2016-11-03 | -$1.58M 10-Q · filed 2016-11-03 | -$5.28M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | -$636.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | -$731.00K 10-Q · filed 2016-08-04 | -$4.43M derived: sum of 3 quarters · filed 2017-03-01 | -$4.35M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | -$95.00K 10-Q · filed 2016-05-05 | -$3.79M derived: sum of 2 quarters · filed 2017-03-01 | -$3.72M derived: sum of 3 quarters · filed 2017-03-01 | -$3.69M derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | -$3.70M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | -$3.62M derived: sum of 2 quarters · filed 2017-03-01 | -$3.59M derived: sum of 3 quarters · filed 2017-03-01 | -$3.61M 10-K · filed 2017-03-01 |
| 2014-09-30 | $75.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | $106.00K derived: sum of 2 quarters · filed 2015-11-04 | $82.00K 10-Q · filed 2015-11-04 | $3.04M derived: sum of 4 quarters · filed 2016-02-25 |
| 2014-06-30 | $31.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $7.00K 10-Q · filed 2015-08-06 | $2.96M derived: sum of 3 quarters · filed 2016-02-25 | $1.41M derived: sum of 4 quarters · filed 2016-02-25 |
| 2014-03-31 | -$24.00K 10-Q · filed 2015-05-08 | $2.93M derived: sum of 2 quarters · filed 2016-02-25 | $1.38M derived: sum of 3 quarters · filed 2016-02-25 | $491.00K derived: sum of 4 quarters · filed 2016-02-25 |
| 2013-12-31 | $2.96M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | $1.40M derived: sum of 2 quarters · filed 2016-02-25 | $515.00K derived: sum of 3 quarters · filed 2016-02-25 | -$3.43M 10-K · filed 2016-02-25 |
| 2013-09-30 | -$1.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | -$2.44M derived: sum of 2 quarters · filed 2014-11-06 | -$6.39M 10-Q · filed 2014-11-06 | |
| 2013-06-30 | -$887.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | -$4.84M 10-Q · filed 2014-08-07 | ||
| 2013-03-31 | -$3.95M 10-Q · filed 2014-05-09 | |||
| 2012-12-31 | -$3.71M 10-K · filed 2015-03-03 | |||
| 2011-12-31 | -$2.49M 10-K · filed 2014-02-27 | |||
| 2010-12-31 | -$1.69M 10-K · filed 2013-02-28 | |||
| 2009-12-31 | -$689.00K 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |